You are here:

emtricitabine / tenofovir / rilpivirine (Eviplera)


Following an abbreviated submission:
emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg, rilpivirine (as hydrochloride) 25mg, film-coated tablet (Eviplera®) is accepted for use in NHS Scotland.
Indication under review: treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.
As with other antiretroviral therapies, genotypic resistance testing should inform the use of Eviplera®. This combination tablet has been shown to be bioequivalent to the individual components given separately. It is available at pro rata cost to the individual components and may be used to simplify the regimen of patients for whom this combination of HIV therapies is appropriate at the doses provided in this fixed dose combination.

Drug Details

Drug Name: emtricitabine / tenofovir / rilpivirine (Eviplera)
SMC Drug ID: 759/12
Manufacturer: Gilead Sciences Ltd
Indication: For the treatment of HIV-1 infection in adults
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 13 February 2012